In 2021, the Global Inflammatory Bowel Disease Treatment market was worth around USD 19.3 Billion.
With the increasing expenditure incurred on Inflammatory Bowel Disease Treatment worldwide, the market is expected to reach a worth of about USD 35.1 Billion by the end of 2032, with a projected CAGR of 5.7% from 2022 to 2032. From 2017 to 2021, the Inflammatory Bowel Disease Treatment Market experienced a growth of 4.7%.
| Attributes | Details |
|---|---|
| Global Inflammatory Bowel Disease Treatment Market Size (2021) | USD 19.3 Billion |
| Global Inflammatory Bowel Disease Treatment Market Size (2022) | USD 20.2 Billion |
| Projected Market Value (2032) | USD 35.1 Billion |
| Global Market Growth Rate (2022 to 2032) | 5.7% CAGR |
| United States Growth Rate (2022 to 2032) | 6.4% CAGR |
| Share of Top 5 Countries | 61% |
| Key Companies Profiled | AbbVie Inc.; Biogen; Johnson & Johnson Services, Inc.; Amgen Inc.; UCB S.A.; Novartis AG; Takeda Pharmaceutical Company Limited; Merck & Co., Inc.; Pfizer Inc.; Eli Lilly |
Inflammatory Bowel Disease can occur at any age, although the disease is most common in adolescents and adults between the ages of 15 and 35. Diet and Stress do not cause inflammatory bowel disease but they can worsen the conditions. According to some recent research, hereditary, genetic, and environmental factors contribute to the disease’s development.
According to a 2019 estimate from the Crohn's and Colitis Foundation, 1.6 million Americans have inflammatory bowel disease. In addition, the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) estimates that in 2020, there were about 3.4 million people in Europe who have IBD of some kind. IBD is affecting more and more people, which increases the need for efficient treatment solutions.
In the forthcoming years, the Inflammatory Bowel Disease Treatment market is expected to expand due to the rising use of biologics for the treatment of inflammatory bowel disease and the release of potent pipeline medications including Risankizumab, Ustekinumab, Tofacitinib, and upadacitinib.
In the upcoming years, the Inflammatory Bowel Disease Treatment market expansion is expected to be boosted by an increase in initiatives taken by various organizations to address the difficulties in the creation of novel therapies.
For instance, the Crohn's and Colitis Foundation published a five-year plan in May 2019 to identify gaps in IBD research, development, and care. Additionally, the European Chronic Disease Alliance has made a lot of efforts to enhance the quality of life for people with inflammatory bowel disease.
North America holds the largest Inflammatory Bowel Disease Treatment market. In 2021, North America contributed to around 40% of the global revenue. As of 2019, there were 730 clinical trials for IBD, including drug development, observational studies, and others, according to the USA National Library of Medicine. Of these, 268 clinical trials were carried out only in the USA.
A substantial portion of the IBD market in North America is held by Canada. The number of Canadians with IBD is almost around 300,000. It is anticipated that treating Canadians with IBD will cost USD 1.28 Billion each year. The Quebec government launched a biosimilars initiative in 2021, according to announcements made by the minister of health and social services, Christian Dubé, patients will transition from original biologic medications to their biosimilar equivalents.
Besides, Asia-Pacific accounts for a promising Inflammatory Bowel Disease Treatment market. This is mainly due to the growing access to healthcare, increasing per capita medical expenditure, and rise in the number of patients with inflammatory bowel disease. The commonness of inflammatory bowel disease is higher in Asian countries including India, China, and Japan.
With 1.5 million IBD patients in 2020, India surpassed the USA as the nation with the most IBD patients. In India, only 3% of patients use biologics, a much lower percentage than in Western nations. Infliximab and Adalimumab, two biologics, have IBD approval in India. Since June 2020, Vedolizumab has also been approved.
A significant portion of all cases of inflammatory bowel disease is seen in Japan. Only infliximab and Adalimumab are approved in Japan for the treatment of both UC and CD, and the USA Food and Drug Administration approved five biological drugs for the treatment of IBD in 2016.
The USA has the largest market for Inflammatory Bowel Disease Treatment, which is projected to reach a valuation of USD 13.6 Billion by 2032. From 2017 to 2021, the Inflammatory Bowel Disease Treatment market in the USA grew at a CAGR of 4.7% and is expected to experience a CAGR of 6.4% in the next ten years. Between 2022 and 2032, the USA is expected to be a market with a USD 6.2 Billion absolute dollar opportunity.
According to the Crohn's and Colitis Foundation (CCFA), the number of new cases of Inflammatory Bowel Disease reported in the USA each year exceeds 70,000. Infliximab, Adalimumab, Certolizumab Pegol, and Golimumab are the four anti-TNF medications that have been authorized for the treatment of IBD in the USA. Two anti-integrin biologics, Natalizumab and Vedolizumab, have been licensed for the treatment of IBD, and biosimilars for both anti-TNF medications have been created. In the USA, the biologic Stekinumab, which inhibits the cytokines IL-12 and IL-23, has been licensed for the treatment of Crohn's disease.
In 2021, China was the second-largest Inflammatory Bowel Disease Treatment Market after the USA. The market in the country is expected to reach a valuation of USD 4.2 Billion by 2032. From the year 2017 to 2021 China’s Inflammatory Bowel Disease Treatment Market experienced a CAGR of 5.5% and is projected to see a similar CAGR of 6.8% in the next ten years. By 2032, China is expected to be an absolute dollar opportunity of USD 2 Billion.
A huge portion of the population smokes in China owing to the country's rising industrialization and evolving lifestyle. The World Bank estimates that in 2016, 48.4% of all male smokers were in China. Smoking has a negative impact on both the small and large intestines, which raises the prevalence of IBD treatment in China.
Reistone Biopharma Co. Ltd., a Chinese biopharmaceutical company in the clinical stages, reported positive findings from a phase II clinical trial that assessed the safety and effectiveness of its drug candidate, SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, for the treatment of moderate-to-severe ulcerative colitis. The trials are being carried out in various locations, such as China, the USA, and other countries. The company was considering launching a phase III clinical trial in 2021.
The market in the United Kingdom is expected to grow from USD 842.5 Million in 2017 to reach a valuation of USD 1.4 Billion by 2032. During the next 10 years, the market in the country is expected to grow at a CAGR of 4.6% to gross an absolute dollar opportunity of USD 509 Million during the forecast period.
Crohn’s Disease is seen to be the most common Inflammatory Bowel Disease. Revenue through the treatment of Crohn’s Disease expanded at a CAGR of 5% from 2017 to 2021 and is projected to grow at a CAGR of 6% from 2022 to 2032.
In 2021, revenue from Crohn's Disease treatment outscored the management of Crohn's Disease 2021 with a market share close to 60 percent. That with the increase in cases has helped to authorize the use of more and more biologics in the marketplace for the treatment of Inflammatory Bowel Disease.
According to Crohn’s and Colitis Foundation, around 25% of patients with Crohn's disease in the USA are prescribed biologics. Moreover, the popularity of Crohn’s disease is about 319 per 100,000 population in North America, while in Europe it is about 322 per 100,000 population.
The Inflammatory Bowel Disease Treatment market is moderately competitive and has numerous players. The key companies operating in the Inflammatory Bowel Disease Treatment Market are AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Pfizer Inc., and Eli Lilly. To secure a dominating position in the market making key players are focusing on introducing new products through collaborations and partnerships.
Some of the recent developments by the key providers of Inflammatory Bowel Disease Treatment are as follows:
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ Million) Forecast by Type, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Drug Case, 2017 to 2032
Table 4: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 6: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 7: North America Market Value (US$ Million) Forecast by Type, 2017 to 2032
Table 8: North America Market Value (US$ Million) Forecast by Drug Case, 2017 to 2032
Table 9: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 12: Latin America Market Value (US$ Million) Forecast by Type, 2017 to 2032
Table 13: Latin America Market Value (US$ Million) Forecast by Drug Case, 2017 to 2032
Table 14: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 17: Europe Market Value (US$ Million) Forecast by Type, 2017 to 2032
Table 18: Europe Market Value (US$ Million) Forecast by Drug Case, 2017 to 2032
Table 19: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 21: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 22: Asia Pacific Market Value (US$ Million) Forecast by Type, 2017 to 2032
Table 23: Asia Pacific Market Value (US$ Million) Forecast by Drug Case, 2017 to 2032
Table 24: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 25: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 26: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 27: MEA Market Value (US$ Million) Forecast by Type, 2017 to 2032
Table 28: MEA Market Value (US$ Million) Forecast by Drug Case, 2017 to 2032
Table 29: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 30: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Figure 1: Global Market Value (US$ Million) by Type, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Drug Case, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 5: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 9: Global Market Value (US$ Million) Analysis by Type, 2017 to 2032
Figure 10: Global Market Value Share (%) and BPS Analysis by Type, 2022 to 2032
Figure 11: Global Market Y-o-Y Growth (%) Projections by Type, 2022 to 2032
Figure 12: Global Market Value (US$ Million) Analysis by Drug Case, 2017 to 2032
Figure 13: Global Market Value Share (%) and BPS Analysis by Drug Case, 2022 to 2032
Figure 14: Global Market Y-o-Y Growth (%) Projections by Drug Case, 2022 to 2032
Figure 15: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 16: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 17: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 21: Global Market Attractiveness by Type, 2022 to 2032
Figure 22: Global Market Attractiveness by Drug Case, 2022 to 2032
Figure 23: Global Market Attractiveness by Route of Administration, 2022 to 2032
Figure 24: Global Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 25: Global Market Attractiveness by Region, 2022 to 2032
Figure 26: North America Market Value (US$ Million) by Type, 2022 to 2032
Figure 27: North America Market Value (US$ Million) by Drug Case, 2022 to 2032
Figure 28: North America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 30: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 34: North America Market Value (US$ Million) Analysis by Type, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Type, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Type, 2022 to 2032
Figure 37: North America Market Value (US$ Million) Analysis by Drug Case, 2017 to 2032
Figure 38: North America Market Value Share (%) and BPS Analysis by Drug Case, 2022 to 2032
Figure 39: North America Market Y-o-Y Growth (%) Projections by Drug Case, 2022 to 2032
Figure 40: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 41: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 42: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 46: North America Market Attractiveness by Type, 2022 to 2032
Figure 47: North America Market Attractiveness by Drug Case, 2022 to 2032
Figure 48: North America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 49: North America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 50: North America Market Attractiveness by Country, 2022 to 2032
Figure 51: Latin America Market Value (US$ Million) by Type, 2022 to 2032
Figure 52: Latin America Market Value (US$ Million) by Drug Case, 2022 to 2032
Figure 53: Latin America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 55: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 59: Latin America Market Value (US$ Million) Analysis by Type, 2017 to 2032
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Type, 2022 to 2032
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Type, 2022 to 2032
Figure 62: Latin America Market Value (US$ Million) Analysis by Drug Case, 2017 to 2032
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Drug Case, 2022 to 2032
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Drug Case, 2022 to 2032
Figure 65: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 71: Latin America Market Attractiveness by Type, 2022 to 2032
Figure 72: Latin America Market Attractiveness by Drug Case, 2022 to 2032
Figure 73: Latin America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 74: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 75: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 76: Europe Market Value (US$ Million) by Type, 2022 to 2032
Figure 77: Europe Market Value (US$ Million) by Drug Case, 2022 to 2032
Figure 78: Europe Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 80: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 84: Europe Market Value (US$ Million) Analysis by Type, 2017 to 2032
Figure 85: Europe Market Value Share (%) and BPS Analysis by Type, 2022 to 2032
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Type, 2022 to 2032
Figure 87: Europe Market Value (US$ Million) Analysis by Drug Case, 2017 to 2032
Figure 88: Europe Market Value Share (%) and BPS Analysis by Drug Case, 2022 to 2032
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Drug Case, 2022 to 2032
Figure 90: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 91: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 96: Europe Market Attractiveness by Type, 2022 to 2032
Figure 97: Europe Market Attractiveness by Drug Case, 2022 to 2032
Figure 98: Europe Market Attractiveness by Route of Administration, 2022 to 2032
Figure 99: Europe Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 100: Europe Market Attractiveness by Country, 2022 to 2032
Figure 101: Asia Pacific Market Value (US$ Million) by Type, 2022 to 2032
Figure 102: Asia Pacific Market Value (US$ Million) by Drug Case, 2022 to 2032
Figure 103: Asia Pacific Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 104: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 105: Asia Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 106: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 109: Asia Pacific Market Value (US$ Million) Analysis by Type, 2017 to 2032
Figure 110: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2022 to 2032
Figure 111: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2022 to 2032
Figure 112: Asia Pacific Market Value (US$ Million) Analysis by Drug Case, 2017 to 2032
Figure 113: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Case, 2022 to 2032
Figure 114: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Case, 2022 to 2032
Figure 115: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 116: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 117: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 118: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 119: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 120: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 121: Asia Pacific Market Attractiveness by Type, 2022 to 2032
Figure 122: Asia Pacific Market Attractiveness by Drug Case, 2022 to 2032
Figure 123: Asia Pacific Market Attractiveness by Route of Administration, 2022 to 2032
Figure 124: Asia Pacific Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 125: Asia Pacific Market Attractiveness by Country, 2022 to 2032
Figure 126: MEA Market Value (US$ Million) by Type, 2022 to 2032
Figure 127: MEA Market Value (US$ Million) by Drug Case, 2022 to 2032
Figure 128: MEA Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 129: MEA Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 130: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 131: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 132: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 134: MEA Market Value (US$ Million) Analysis by Type, 2017 to 2032
Figure 135: MEA Market Value Share (%) and BPS Analysis by Type, 2022 to 2032
Figure 136: MEA Market Y-o-Y Growth (%) Projections by Type, 2022 to 2032
Figure 137: MEA Market Value (US$ Million) Analysis by Drug Case, 2017 to 2032
Figure 138: MEA Market Value Share (%) and BPS Analysis by Drug Case, 2022 to 2032
Figure 139: MEA Market Y-o-Y Growth (%) Projections by Drug Case, 2022 to 2032
Figure 140: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 141: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 142: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 143: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 144: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 145: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 146: MEA Market Attractiveness by Type, 2022 to 2032
Figure 147: MEA Market Attractiveness by Drug Case, 2022 to 2032
Figure 148: MEA Market Attractiveness by Route of Administration, 2022 to 2032
Figure 149: MEA Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 150: MEA Market Attractiveness by Country, 2022 to 2032
The global Inflammatory Bowel Disease Treatment Market was valued at USD 20.2 Billion in 2022 and is expected to be a USD 14.9 Billion absolute dollar opportunity by 2032.
Over the projected period, the Inflammatory Bowel Disease Treatment Market is expected to increase at a CAGR of 5.7%, reaching a value of USD 35.1 Billion by 2032.
The Inflammatory Bowel Disease Treatment Market expanded at a CAGR of 4.7% from 2017 through 2021.
Crohn’s Disease is seen to be the most common Inflammatory Bowel Disease. Revenue through the treatment of Crohn’s Disease expanded at a CAGR of 5% from 2017 to 2021 and is projected to grow at a CAGR of 6% by 2032.
AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Pfizer Inc., are some of the key players in the Inflammatory Bowel Disease Treatment Industry.
The USA, United Kingdom, China, Japan, and South Korea are expected to drive the most Inflammatory Bowel Disease Treatment.
Explore Similar Insights
Inflammatory Bowel Disease Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
